Cryptotanshinone, an orally bioactive herbal compound from <scp>D</scp>anshen, attenuates atherosclerosis in apolipoprotein <scp>E</scp>‐deficient mice: role of lectin‐like oxidized LDL receptor‐1 (<scp>LOX</scp>‐1)

Abstract

CTS was shown to have anti-atherosclerotic activity, which was mediated through inhibition of the LOX-1-mediated signalling pathway. This suggests that CTS is a vasculoprotective drug that has potential therapeutic value for the clinical treatment of atherosclerotic cardiovascular diseases.